Inovio Financial Statements From 2010 to 2026

INO Stock

USD 1.69 0.05 2.87%

Inovio Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Inovio Pharmaceuticals' valuation are provided below:

Gross Profit

-56.6 M

Market Capitalization

116.1 M

Enterprise Value Revenue

431.9524

Revenue

182.3 K

Earnings Share

(2.72)

We have found one hundred twenty available fundamental trends for Inovio Pharmaceuticals, which can be analyzed and compared to other ratios and to its competitors. Self-guided Investors are advised to confirm Inovio Pharmaceuticals' regular fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 3rd of January 2026, Market Cap is likely to drop to about 42.5 M. In addition to that, Enterprise Value is likely to grow to about (3.6 M)

Inovio Pharmaceuticals Total Revenue

237,898

Check Inovio Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inovio Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.4 M, Interest Expense of 194.3 K or Total Revenue of 237.9 K, as well as many indicators such as Price To Sales Ratio of 195, Dividend Yield of 0.0053 or PTB Ratio of 0.62. Inovio financial statements analysis is a perfect complement when working with Inovio Pharmaceuticals Valuation or Volatility modules.

Build AI portfolio with Inovio Stock

Check out the analysis of Inovio Pharmaceuticals Correlation against competitors.

To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.

Inovio Pharmaceuticals Balance Sheet

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Total Assets

130.8 M

130.2 M

183.3 M

Slightly volatile

Short and Long Term Debt Total

21.3 M

13.6 M

63.3 M

Slightly volatile

Total Current Liabilities

24.1 M

40.6 M

34.6 M

Slightly volatile

Total Stockholder Equity

94.3 M

78.8 M

131 M

Slightly volatile

Property Plant And Equipment Net

7.7 M

13.5 M

12.1 M

Slightly volatile

Accounts Payable

5.1 M

7.4 M

7.1 M

Slightly volatile

Cash

79.5 M

75.7 M

50.2 M

Slightly volatile

Non Current Assets Total

27.7 M

17.7 M

34.4 M

Very volatile

Cash And Short Term Investments

92.3 M

108.2 M

133.4 M

Slightly volatile

Net Receivables

1.3 M

1.4 M

5.3 M

Very volatile

Common Stock Shares Outstanding

47.3 M

31.2 M

67.4 M

Pretty Stable

Liabilities And Stockholders Equity

130.8 M

130.2 M

183.3 M

Slightly volatile

Non Current Liabilities Total

12 M

10.8 M

17.3 M

Slightly volatile

Other Stockholder Equity

2.2 B

2.1 B

1 B

Slightly volatile

Total Liabilities

36 M

51.4 M

51.9 M

Slightly volatile

Property Plant And Equipment Gross

34.1 M

32.5 M

18 M

Slightly volatile

Total Current Assets

103 M

112.5 M

148.9 M

Slightly volatile

Intangible Assets

2.3 M

2.4 M

4.2 M

Slightly volatile

Other Current Liabilities

15.7 M

30.3 M

23.1 M

Slightly volatile

Other Liabilities

35 K

36.9 K

3.3 M

Slightly volatile

Non Currrent Assets Other

2.5 M

2.3 M

2.9 M

Pretty Stable

Common Stock Total Equity

216.4 K

227.8 K

1.9 M

Slightly volatile

Short Term Debt

2.7 M

2.9 M

6.8 M

Very volatile

Common Stock

30.9 K

32.5 K

1.9 M

Slightly volatile

Property Plant Equipment

5.2 M

8.9 M

8.2 M

Slightly volatile

Current Deferred Revenue

2.1 M

1.2 M

2.6 M

Pretty Stable

Short Term Investments

30.9 M

32.5 M

84.5 M

Slightly volatile

Capital Surpluse

2.1 B

2 B

995.2 M

Slightly volatile

Long Term Investments

1.4 M

1.5 M

7.8 M

Slightly volatile

Net Invested Capital

74.8 M

78.8 M

164.5 M

Very volatile

Net Working Capital

68.3 M

71.9 M

134.2 M

Pretty Stable

Capital Stock

30.9 K

32.5 K

103.3 K

Pretty Stable

Long Term Debt Total

14.2 M

15 M

51.9 M

Slightly volatile

Capital Lease Obligations

13.6 M

10.7 M

19.3 M

Slightly volatile

Short and Long Term Debt

13.4 M

15.1 M

16.5 M

Slightly volatile

Inovio Pharmaceuticals Income Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Depreciation And Amortization

2.4 M

3.6 M

3.2 M

Slightly volatile

Interest Expense

194.3 K

204.5 K

7.3 M

Pretty Stable

Total Revenue

237.9 K

250.4 K

12.9 M

Slightly volatile

Other Operating Expenses

76.2 M

129.5 M

111.3 M

Slightly volatile

Research Development

53.3 M

87 M

80.2 M

Slightly volatile

Cost Of Revenue

3.4 M

3.6 M

40.3 M

Pretty Stable

Total Operating Expenses

75.9 M

127.7 M

111 M

Slightly volatile

Selling General Administrative

44.7 B

42.5 B

7.3 B

Slightly volatile

Interest Income

3.8 M

5.5 M

3.5 M

Slightly volatile

Reconciled Depreciation

3.7 M

2.8 M

4 M

Pretty Stable

Selling And Marketing Expenses

44.6 B

42.5 B

7.3 B

Slightly volatile

Inovio Pharmaceuticals Cash Flow Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Begin Period Cash Flow

32.2 M

16.5 M

41.3 M

Pretty Stable

Depreciation

2.4 M

3.6 M

3.2 M

Slightly volatile

Capital Expenditures

533 K

561 K

1.7 M

Very volatile

Total Cash From Financing Activities

58.6 M

59.2 M

83.7 M

Pretty Stable

End Period Cash Flow

79.5 M

75.7 M

50.2 M

Slightly volatile

Stock Based Compensation

5.6 M

5.9 M

9.2 M

Slightly volatile

Change To Netincome

20.1 M

34.5 M

19.7 M

Slightly volatile

Issuance Of Capital Stock

30.8 M

32.4 M

66.4 M

Pretty Stable

Financial Ratios

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Price To Sales Ratio

195

205

803

Pretty Stable

Dividend Yield

0.0053

0.005

0.0052

Slightly volatile

PTB Ratio

0.62

0.65

115

Very volatile

Days Sales Outstanding

1.9 K

1.8 K

626

Slightly volatile

Book Value Per Share

3.5

2.9

3.0566

Pretty Stable

Average Payables

3.7 M

5 M

7.8 M

Slightly volatile

Stock Based Compensation To Revenue

33.09

34.83

7.9781

Slightly volatile

Capex To Depreciation

0.17

0.18

0.5922

Slightly volatile

PB Ratio

0.62

0.65

115

Very volatile

Inventory Turnover

1.64

2.04

2.2016

Slightly volatile

Days Of Inventory On Hand

197

185

166

Slightly volatile

Payables Turnover

0.12

0.13

0.1465

Slightly volatile

Sales General And Administrative To Revenue

161

153

35.3819

Slightly volatile

Average Inventory

609.4 K

487.5 K

453.9 K

Very volatile

Research And Ddevelopement To Revenue

328

313

76.8605

Slightly volatile

Capex To Revenue

2.12

2.02

0.516

Slightly volatile

Cash Per Share

2.26

3.12

3.0139

Pretty Stable

Days Payables Outstanding

3.1 K

2.9 K

3.1 K

Slightly volatile

Income Quality

0.64

0.87

0.8202

Very volatile

Intangibles To Total Assets

0.0396

0.0417

0.1066

Slightly volatile

Current Ratio

4.77

3.18

4.2762

Very volatile

Receivables Turnover

0.2

0.21

3.85

Slightly volatile

Shareholders Equity Per Share

3.47

2.9

3.0507

Pretty Stable

Debt To Equity

0.15

0.16

15.3984

Slightly volatile

Capex Per Share

0.0196

0.0207

0.0483

Slightly volatile

Average Receivables

12.8 M

12.2 M

9.5 M

Slightly volatile

Revenue Per Share

0.0088

0.0092

0.5908

Slightly volatile

Interest Debt Per Share

0.38

0.4

0.3892

Slightly volatile

Debt To Assets

0.1

0.0943

0.408

Slightly volatile

Operating Cycle

1.9 K

1.8 K

637

Slightly volatile

Price Book Value Ratio

0.62

0.65

115

Very volatile

Days Of Payables Outstanding

3.1 K

2.9 K

3.1 K

Slightly volatile

Ebt Per Ebit

1.24

1.1

1.1384

Very volatile

Company Equity Multiplier

2.35

1.49

3.8201

Very volatile

Long Term Debt To Capitalization

0.076

0.08

0.533

Slightly volatile

Total Debt To Capitalization

0.14

0.13

0.5654

Slightly volatile

Debt Equity Ratio

0.15

0.16

15.3984

Slightly volatile

Quick Ratio

4.72

3.18

4.2562

Very volatile

Net Income Per E B T

0.79

0.89

0.986

Slightly volatile

Cash Ratio

2.45

2.14

1.74

Very volatile

Days Of Inventory Outstanding

197

185

166

Slightly volatile

Days Of Sales Outstanding

1.9 K

1.8 K

626

Slightly volatile

Free Cash Flow Operating Cash Flow Ratio

1.16

1.0047

1.0582

Very volatile

Price To Book Ratio

0.62

0.65

115

Very volatile

Fixed Asset Turnover

0.0202

0.0213

4.3816

Slightly volatile

Debt Ratio

0.1

0.0943

0.408

Slightly volatile

Price Sales Ratio

195

205

803

Pretty Stable

Asset Turnover

0.0021

0.0022

0.1184

Slightly volatile

Gross Profit Margin

0.65

0.84

0.9081

Slightly volatile

Price Fair Value

0.62

0.65

115

Very volatile

Inovio Pharmaceuticals Valuation Data

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Market Cap

42.5 M

44.7 M

4.2 B

Pretty Stable

Inovio Fundamental Market Drivers

Inovio Upcoming Events

	6th of March 2024 Upcoming Quarterly Report	View
	8th of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	6th of March 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

About Inovio Pharmaceuticals Financial Statements

Inovio Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how Inovio Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Current Deferred Revenue	1.2 M	2.1 M
Total Revenue	250.4 K	237.9 K
Cost Of Revenue	3.6 M	3.4 M
Stock Based Compensation To Revenue	34.83	33.09
Sales General And Administrative To Revenue	152.91	160.55
Research And Ddevelopement To Revenue	312.54	328.17
Capex To Revenue	2.02	2.12
Revenue Per Share	0.01	0.01
Ebit Per Revenue	(593.59)	(563.91)

Pair Trading with Inovio Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Inovio Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inovio Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Inovio Stock

0.78	AMGN	Amgen Inc	Pair Corr
0.71	KO	Coca Cola	Pair Corr
0.67	XOM	Exxon Mobil Corp Aggressive Push	Pair Corr
0.65	CSCO	Cisco Systems	Pair Corr
0.64	MMM	3M Company	Pair Corr

The ability to find closely correlated positions to Inovio Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Inovio Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Inovio Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Inovio Pharmaceuticals to buy it.

The correlation of Inovio Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Inovio Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Inovio Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Inovio Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Inovio Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Inovio Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inovio Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inovio Pharmaceuticals Stock:

How To Invest In Inovio

Details

Is Inovio Stock a good investment?

Details

What is Inovio Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Inovio Pharmaceuticals Correlation against competitors.

To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.

You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.72)

Revenue Per Share

0.005

Quarterly Revenue Growth

0.14

Return On Assets

(0.64)

Return On Equity

(3.28)

The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Inovio Financial Statements From 2010 to 2026

Inovio Pharmaceuticals Total Revenue

237,898

Inovio Pharmaceuticals Balance Sheet

Inovio Pharmaceuticals Income Statement

Inovio Pharmaceuticals Cash Flow Statement

Financial Ratios

Inovio Pharmaceuticals Valuation Data

Inovio Fundamental Market Drivers

Inovio Upcoming Events

About Inovio Pharmaceuticals Financial Statements

Pair Trading with Inovio Pharmaceuticals

Moving against Inovio Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY